Latest news with #AsymchemLaboratories
Yahoo
3 days ago
- Business
- Yahoo
Binder Excipients Market Research Business Report 2025-2030: Rising Demand for Solid Dosage Forms Spurs Growth, Increasing Focus on Patient-Centric Drug Formulations Expands Opportunities
The global Binder Excipients market, valued at US$2.0 Billion in 2024, is set to reach US$2.7 Billion by 2030 with a CAGR of 5.3%. Key drivers include rising demand for solid dosage forms and advancements in pharmaceutical technology. Notable trends are the shift towards natural excipients and multifunctional products. The report details market forecasts, regional growth, and major players like Asymchem Laboratories and Croda International. Explore in-depth insights for strategic decisions in the evolving binder excipients landscape. Binder Excipients Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Binder Excipients - Global Strategic Business Report" report has been added to global market for Binder Excipients was valued at US$2.0 Billion in 2024 and is projected to reach US$2.7 Billion by 2030, growing at a CAGR of 5.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Binder Excipients market. Binder excipients are essential components in pharmaceutical formulations, playing a crucial role in the manufacturing of solid dosage forms such as tablets and capsules. These substances are responsible for binding the various ingredients in a formulation together, ensuring that the final product is cohesive and stable. Without binders, the active pharmaceutical ingredients (APIs) and other excipients might not combine effectively, leading to issues with tablet integrity, dissolution, and Factors Are Driving the Growth of the Binder Excipients Market?The growth in the binder excipients market is driven by several factors, reflecting the changing dynamics of pharmaceutical manufacturing and consumer demand. One of the primary drivers is the increasing demand for solid dosage forms, such as tablets and capsules, which remain the most popular and convenient forms of medication delivery. This demand is further amplified by the rise in chronic diseases and the need for effective, long-term treatments that rely heavily on well-formulated solid dosage drugs. Another significant factor is the advancement in pharmaceutical technology, particularly in direct compression and high-speed tablet manufacturing, which has created a need for binders with superior compressibility and flow properties. Additionally, the growing focus on patient-centric formulations, including orally disintegrating tablets (ODTs) and pediatric formulations, is driving the demand for specialized binder excipients that can meet specific performance criteria. The shift towards natural and clean-label products is also influencing the market, with consumers and regulators alike pushing for more sustainable and biocompatible excipients. Finally, the expanding pharmaceutical production in emerging markets, driven by the rising healthcare needs and increasing access to medications, is contributing to the growth of the binder excipients market as manufacturers seek reliable and efficient binders to support large-scale production. What Are the Emerging Trends in the Binder Excipients Market?The binder excipients market is witnessing several emerging trends driven by the evolving needs of the pharmaceutical industry and changes in regulatory landscapes. One significant trend is the shift towards natural and sustainable binder excipients, as both consumers and manufacturers increasingly prioritize eco-friendly and renewable sources. Natural binders, derived from plant-based materials such as alginates, gums, and starches, are gaining popularity due to their biocompatibility, lower environmental impact, and the growing demand for clean-label products. Another trend is the increasing use of co-processed excipients, where two or more excipients are combined at a sub-particle level to create a single, multifunctional product. This approach not only enhances the functionality of the binder but also simplifies the formulation process, leading to better product consistency and performance. Regulatory requirements are also shaping the market, with stricter guidelines pushing for higher levels of excipient quality, safety, and traceability. This has led to a greater emphasis on excipient characterization, the adoption of quality-by-design (QbD) principles, and the use of advanced analytical techniques to ensure compliance and reliability in pharmaceutical production. These trends indicate a dynamic market that is continuously adapting to meet the demands of a rapidly changing pharmaceutical landscape. How Are Technological Advancements Shaping the Future of Binder Excipients?Technological advancements are driving significant innovations in the development and application of binder excipients, with a growing emphasis on enhancing performance and meeting specific formulation challenges. One of the most notable trends is the development of multifunctional excipients, which combine binding properties with other functional attributes such as disintegration, lubrication, and controlled release. This innovation simplifies the formulation process, reduces the number of excipients needed, and improves the efficiency of manufacturing. Additionally, the rise of direct compression technology has led to the demand for binders that perform well without the need for wet granulation, a traditionally complex and time-consuming process. This has spurred the development of binders with superior compressibility and flow characteristics, enabling faster and more cost-effective production of tablets. Moreover, the increasing focus on personalized medicine and the production of small-batch, high-potency drugs has necessitated the creation of binders that can support the precise formulation of low-dose medications. As technology continues to evolve, it is expected that binder excipients will become even more specialized, offering tailored solutions to meet the diverse needs of modern pharmaceutical Scope Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Asymchem Laboratories (Tianjin), Colorcon, Inc., Croda International Plc, Fuji Chemical Industry Co., Ltd., Ingredion, Inc. and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Cellulosics segment, which is expected to reach US$1.0 Billion by 2030 with a CAGR of a 5.7%. The Lactose-Based Binder Excipients segment is also set to grow at 5.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $538.4 Million in 2024, and China, forecasted to grow at an impressive 5.1% CAGR to reach $421.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments Type (Cellulosics, Lactose-Based Binder Excipients, Polyol Excipients, Povidone-Based Binder Excipients, Starch & Polysaccharides-Based Binder Excipients, Other Types) Application (Tablets & Capsules, Solution-Based) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 194 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2 Billion Forecasted Market Value (USD) by 2030 $2.7 Billion Compound Annual Growth Rate 5.3% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Binder Excipients - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Increasing Prevalence of Chronic Diseases Drives Adoption of Binder Excipients in Long-Term Medications Rising Demand for Solid Dosage Forms Spurs Growth in Binder Excipients Market Increasing Focus on Patient-Centric Drug Formulations Expands Addressable Market Opportunity Shift towards Multifunctional Excipients Strengthens Business Case for Advanced Binder Solutions Growing Trend of Personalized Medicine Generates Demand for Customized Binder Excipients Sustainability Concerns Throw the Spotlight on Bio-Based and Eco-Friendly Binder Excipients Innovation in Material Science Spurs Growth in High-Performance Binder Excipients Increasing Use of Co-Processed Excipients Expands Market for Binder Excipients Consumer Preference for Low-Dose and High-Potency Drugs Propels Need for Specialized Binders Advances in Biopharmaceuticals Sustain Growth in Demand for Innovative Binder Excipients FOCUS ON SELECT PLAYERS:Some of the 42 companies featured in this report Asymchem Laboratories (Tianjin) Colorcon, Inc. Croda International Plc Fuji Chemical Industry Co., Ltd. Ingredion, Inc. Maple Biotech Pvt., Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Binder Excipients Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
12-02-2025
- Business
- Yahoo
February 2025's Estimated Value Stocks For Savvy Investors
As global markets grapple with economic uncertainties, including tariff tensions and mixed employment data, investors are keenly observing the fluctuations in major indices like the S&P 500 and Nasdaq Composite. Amid these conditions, identifying stocks that may be undervalued can offer potential opportunities for those looking to navigate the current market landscape effectively. In this context, a good stock is often characterized by strong fundamentals and resilience against broader market volatility. Name Current Price Fair Value (Est) Discount (Est) Gilead Sciences (NasdaqGS:GILD) US$96.14 US$191.74 49.9% National World (LSE:NWOR) £0.227 £0.45 49.5% On the Beach Group (LSE:OTB) £2.495 £4.94 49.5% TCI (TPEX:8436) NT$119.00 NT$237.00 49.8% Hanjaya Mandala Sampoerna (IDX:HMSP) IDR575.00 IDR1141.10 49.6% APAC Realty (SGX:CLN) SGD0.455 SGD0.91 49.9% Smurfit Westrock (NYSE:SW) US$53.64 US$107.04 49.9% Array Technologies (NasdaqGM:ARRY) US$6.87 US$13.66 49.7% SK D&D (KOSE:A210980) ₩7110.00 ₩14097.07 49.6% Pantoro (ASX:PNR) A$0.135 A$0.27 49.5% Click here to see the full list of 899 stocks from our Undervalued Stocks Based On Cash Flows screener. Here's a peek at a few of the choices from the screener. Overview: Saudi Basic Industries Corporation operates in the global manufacture, marketing, and distribution of chemicals, polymers, plastics, agri-nutrients, and metal products with a market cap of SAR203.40 billion. Operations: The company's revenue is primarily derived from its Petrochemicals & Specialties segment, which generated SAR129.98 billion, and its Agri-Nutrients segment, contributing SAR10.34 billion. Estimated Discount To Fair Value: 29.9% Saudi Basic Industries is trading at SAR67.8, significantly below its estimated fair value of SAR96.76, indicating it may be undervalued based on cash flows. Despite a dividend yield of 5.01% not being well covered by earnings or free cash flows, the company's earnings are forecast to grow significantly over the next three years at 52% per year, outpacing the Saudi Arabian market's growth rate and suggesting strong future cash flow potential. According our earnings growth report, there's an indication that Saudi Basic Industries might be ready to expand. Get an in-depth perspective on Saudi Basic Industries' balance sheet by reading our health report here. Overview: Asymchem Laboratories (Tianjin) Co., Ltd. operates as a contract development and manufacturing organization (CDMO) providing services to the pharmaceutical industry, with a market cap of CN¥28.22 billion. Operations: The company generates revenue of CN¥5.57 billion from its Pharmaceutical Technology segment. Estimated Discount To Fair Value: 10.1% Asymchem Laboratories (Tianjin), trading at CN¥81.9, is slightly undervalued against its fair value estimate of CN¥91.11. Despite a challenging year with net profit dropping significantly due to the absence of large orders and increased R&D expenses, earnings are expected to grow significantly over the next three years. The company has shown resilience with quarter-on-quarter revenue growth and strong order momentum from European and American markets, supporting future cash flow prospects. The analysis detailed in our Asymchem Laboratories (Tianjin) growth report hints at robust future financial performance. Dive into the specifics of Asymchem Laboratories (Tianjin) here with our thorough financial health report. Overview: Beijing Easpring Material Technology Co., Ltd. develops, produces, and sells lithium battery materials both in China and internationally, with a market cap of CN¥20.29 billion. Operations: The company generates revenue through its development, production, and sale of lithium battery materials across domestic and international markets. Estimated Discount To Fair Value: 33.3% Beijing Easpring Material Technology, trading at CN¥40.06, is significantly undervalued with a fair value estimate of CN¥60.02, offering potential for cash flow-driven investment returns. Despite a low forecasted return on equity and unsustainable dividend coverage by free cash flows, the company anticipates robust revenue growth of 28.6% annually, outpacing the Chinese market average. Recent shareholder meetings focus on optimizing fund allocation from previous share offerings to enhance project investments. Upon reviewing our latest growth report, Beijing Easpring Material TechnologyLTD's projected financial performance appears quite optimistic. Navigate through the intricacies of Beijing Easpring Material TechnologyLTD with our comprehensive financial health report here. Discover the full array of 899 Undervalued Stocks Based On Cash Flows right here. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SASE:2010 SZSE:002821 and SZSE:300073. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
